Rare Diseases
- Business Wire
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
− Analysis of Safety and Efficacy for up to 2.5 years with TAKHYZRO is Consistent with Initial Period of Treatment,…
Read More » - Business
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
Osaka, Japan: Delivered FY2020 Management Guidance with Results Driven by +16% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO ® +26.2%…
Read More » - Health
Illuminating the Heroes of Rare Diseases
Sydney, Australia: With a mission of empowering the rare disease community, Illumina has today partnered with medical researchers and families…
Read More » - Business
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
Osaka, Japan: FY2020 Q3 Year-to-Date Results Driven by 15% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO +24.0%, TAKHZYRO…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More » - Health
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
Osaka, Japan: Three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) to…
Read More » - Technology
Takeda Accelerates Digital Transformation with Accenture and AWS
Osaka, Japan & Seattle, New York, United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and…
Read More » - Health
Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis
Osaka, Japan: Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with…
Read More » - United States
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Japan & United States: − Potential first-in-class therapy designed to treat the underlying cause of liver disease associated…
Read More »